Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLC

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.